1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

iPierian raises $30m to target tau, spin out complement program

 
• By Mandy Jackson

South San Francisco-based iPierian raised $30m in private financing to prepare its monoclonal antibody targeting the tau protein for clinical development and to fund a series A round for the new company True North Therapeutics, which will develop iPierian's monoclonal antibody that selectively inhibits the classical complement pathway for the treatment of rare diseases.

South San Francisco-based iPierian raised $30m in private financing to prepare its monoclonal antibody targeting the tau protein for clinical development and to fund a series A round for the new company True North Therapeutics, which will develop iPierian's monoclonal antibody that selectively inhibits the classical complement pathway for the treatment of rare diseases.

IPierian CEO Nancy Stagliano said 16 months ago that the company would focus on the development of monoclonal antibodies targeting tau and the complement pathway for neurodegenerative diseases (scripintelligence.com,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

More from Therapy Areas

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.